Review



anti mcl 1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc anti mcl 1
    Anti Mcl 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1769 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Antibody/pm41762588-157-35-36
    Average 96 stars, based on 1769 article reviews
    anti mcl 1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: First-in-Class Dual PDGFR/Carbonic Anhydrase IX/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents.
    Article Snippet: The following specific antibodies were purchased from Cell Signaling: anti-PDGFRα(D1E1E), antiphosphoPDGFRα/β Y849/857 (C43E9), anti-STAT3 (79D7), antiphospho-STAT3 Y705 (D3A7), anti-Akt (C67E7), antiphospho-Akt S473 (D9E), anti-ERK1/2, anti-phosphoERK1/2 T202/Y204, anti-PARP-1 (46D11), anti-Mcl-1 (D35A5), anti-caspase-9, and anti-HSP70.

    Article Title: First-in-Class Dual PDGFR/Carbonic Anhydrase IX/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents
    Article Snippet: After the 72 h incubation period, 20 μL of resazurin (Merck; final concentration 10 μg/mL) solution was added for 4 h. Fluorescence of resorufin corresponding to live cells was measured at 560/590 nm (excitation/emission) using Infinite F Plex (Tecan).

    Incubation:

    Article Title: Synthesis, structural characterization, computational studies, and anticancer evaluation of novel rufloxacin Schiff base metal complexes with involvement of Mcl-1 modulation in breast cancer cells.
    Article Snippet: Background and Objective: Breast cancer remains a leading cause of cancer-related mortality among women worldwide, emphasizing the urgent need for the development of novel and effective metal-based chemotherapeutics.. This study aimed to synthesize and characterize a new Schiff base ligand derived from rufloxacin and to evaluate the anticancer potential of its metal complexes against triple-negative breast cancer (TNBC) cells, focusing on Mcl-1 protein suppression as a mechanistic target.. Methods: A novel Schiff base ligand, N,N-phenylene(bis(9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid)) dihydrochloride (H2Ruf-o-phdn⋅2HCl), was synthesized via the condensation of rufloxacin hydrochloride with o-phenylenediamine in ethanol.

    Article Title: UPR/ATF4/Noxa pathway overactivation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids.
    Article Snippet: Immunoblotting: equal amounts of proteins were loaded on 4-15% SDS-PAGE precast gel and transferred onto a PDVF membrane (Bio-Rad). .. Membranes were blocked 1 h with 5% nonfat dry milk in 0.05% Tween-TBS 1X then incubated with the following primary antibodies: anti-ATF4 (#11815), anti-BAK (#3814), anti-BAX (#2774), anti-BCL-xL (#2764), anti-BIM (#2819), anti-BiP (#3177), anti-CASPASE 3 (#9662), anti-CASPASE 8 (#9496), anti-CHOP (#2895), antiDR5 (#8074), anti-MCL-1 (#5453), anti-PARP (#9542), anti-PUMA (#12450) (Cell Signaling Technology); anti-Noxa (#114C307) (Calbiochem); anti-Actin (#MAB1501) (Merck Millipore); antiTubulin (#T6199-100UL) (DM-labo) and anti-SERCA2 (#NB300-581) (Novus-Bio). .. After incubation with the appropriate horseradish peroxidase-conjugate anti-mouse (#NA931V) (Amersham) or anti-rabbit (#7074) (Cell Signaling Technology), revelation was performed using AR TI CL E IN P RE SS ARTICLE IN PRESS Clarity Western EleCtroLuminescence detection reagent (Bio-Rad) and signal was recorded using ImageQuant800 (Cytiva).

    Fluorescence:

    Article Title: WWOX Induction Promotes Bcl-X L and Mcl-1 Degradation Through a Lysosomal Pathway upon Stress Responses.
    Article Snippet: .. The antibodies used in the detection of specific proteins were anti-Bcl-XL, anti-Mcl-1, anti-Bcl-2, anti-Bax, anti-Bak, anti-Bad (Cell Signaling, Danvers, MA, USA), anti-green fluorescence protein (GFP), anti-WWOX (GeneTex), and anti-β-actin (Sigma). .. The secondary antibodies used were horseradish peroxidase-conjugated goat anti-rabbit IgG or horse anti-mouse IgG (Cell Signaling).

    Article Title: WWOX Induction Promotes Bcl-X L and Mcl-1 Degradation Through a Lysosomal Pathway upon Stress Responses
    Article Snippet: .. The antibodies used in the detection of specific proteins were anti-Bcl-X L , anti-Mcl-1, anti-Bcl-2, anti-Bax, anti-Bak, anti-Bad (Cell Signaling, Danvers, MA, USA), anti-green fluorescence protein (GFP), anti-WWOX (GeneTex), and anti-β-actin (Sigma). .. The secondary antibodies used were horseradish peroxidase-conjugated goat anti-rabbit IgG or horse anti-mouse IgG (Cell Signaling).

    Western Blot:

    Article Title: High Frequency Loss of 17q11.2 and Downregulation of the Cancer Metastasis Suppression microRNA miR-193a-3p in Prostate Cancer Bone Metastasis
    Article Snippet: 60,000 PC3 cells/well were seeded in 6-well plates and transfected with 100 nM of PLAU and CCND1-specific smart pool siRNAs and control non-targeting siRNA (GE Dharmacon, Layfayette, CO, USA) using oligofectamine reagent (Life technologies) according to the manufacturer’s protocols. .. Western blotting was performed as previously described [13] using anti-urokinase (ab24121, Abcam, Cambridge, UK, 1:1000), anti-cyclin D1 (DCS-6, sc-20044, Santa Cruz, CA, USA, 1:500), anti-Mcl-1 (D5V5L, Cell Signaling, Danvers, MA, USA, 39224, 1:1000), anti-RAB27B (ab103418, Abcam), anti-PI3 Kinase p110α (C73F8, Cell Signaling 4249, 1:1000), anti-phospho-PI3 Kinase p85—Tyr458/p55—Tyr199 (Cell Signaling, 4228, 1:1000), antiE-cadherin (Clone HECD-1, Takara, San Jose, CA, USA, M106, 1:1000), anti-N-cadherin (5D5, Abcam, ab98952, 1:1000), anti-vimentin (EP21, Epitomics, Burlingame, CA, USA, 1:3000), anti-CK18 (DC10, NCL-CK18, Novocastra, Newcastle Upon Tyne, UK, 1:3000) and anti-β-Actin (clone AC-15, A5441, Sigma Aldrich, 1:10,000) antibody. .. Cell viability and proliferation were determined using the CellTiter 96 AQueous Cell Proliferation Assay (MTS) (Promega).

    Article Title: High Frequency Loss of 17q11.2 and Downregulation of the Cancer Metastasis Suppression microRNA miR-193a-3p in Prostate Cancer Bone Metastasis
    Article Snippet: 60,000 PC3 cells/well were seeded in 6-well plates and transfected with 100 nM of PLAU and CCND1 -specific smart pool siRNAs and control non-targeting siRNA (GE Dharmacon, Layfayette, CO, USA) using oligofectamine reagent (Life technologies) according to the manufacturer’s protocols. .. Western blotting was performed as previously described [ ] using anti-urokinase (ab24121, Abcam, Cambridge, UK, 1:1000), anti-cyclin D1 (DCS-6, sc-20044, Santa Cruz, CA, USA, 1:500), anti-Mcl-1 (D5V5L, Cell Signaling, Danvers, MA, USA, 39224, 1:1000), anti-RAB27B (ab103418, Abcam), anti-PI3 Kinase p110α (C73F8, Cell Signaling 4249, 1:1000), anti-phospho-PI3 Kinase p85—Tyr458/p55—Tyr199 (Cell Signaling, 4228, 1:1000), anti-E-cadherin (Clone HECD-1, Takara, San Jose, CA, USA, M106, 1:1000), anti-N-cadherin (5D5, Abcam, ab98952, 1:1000), anti-vimentin (EP21, Epitomics, Burlingame, CA, USA, 1:3000), anti-CK18 (DC10, NCL-CK18, Novocastra, Newcastle Upon Tyne, UK, 1:3000) and anti-β-Actin (clone AC-15, A5441, Sigma Aldrich, 1:10,000) antibody. .. Cell viability and proliferation were determined using the CellTiter 96 AQueous Cell Proliferation Assay (MTS) (Promega).



    Similar Products

    96
    Cell Signaling Technology Inc anti mcl 1
    Anti Mcl 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Antibody/pm41762588-157-35-36
    Average 96 stars, based on 1 article reviews
    anti mcl 1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc mcl 1
    Mcl 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Rabbit+mAb/pm41932441-295-5-17
    Average 96 stars, based on 1 article reviews
    mcl 1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti mcl 1
    Anti Mcl 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Antibody/pm41899524-104-25-28
    Average 96 stars, based on 1 article reviews
    anti mcl 1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc mcl
    Mcl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Antibody/pm41896944-68-16-20
    Average 96 stars, based on 1 article reviews
    mcl - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Proteintech mcl 1
    Mcl 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/MCL1+Antibody/pm41872189-64-38-40
    Average 96 stars, based on 1 article reviews
    mcl 1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc αmcl1
    (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of <t>MCL1</t> in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) 30 µM ABT-199/Venetoclax and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.
    αmcl1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mcl+1/Mcl-1+Rabbit+mAb/bio_rxiv__64898__2026__03__20__712678-206-37-39
    Average 96 stars, based on 1 article reviews
    αmcl1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of MCL1 in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) 30 µM ABT-199/Venetoclax and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.

    Journal: bioRxiv

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

    doi: 10.64898/2026.03.20.712678

    Figure Lengend Snippet: (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of MCL1 in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) 30 µM ABT-199/Venetoclax and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.

    Article Snippet: To assess BCL2 family members, cells were incubated with 30 μl αCD16/32 Fc-Block (1:20 in PermWash Buffer) for 15 min, followed by incubation with 30 μl of following antibodies: αBIM (1:100, Abcam, ab32158), αBCL2-PE (1:100, Biolegend, 633507), αMCL1 (1:100, Cell Signaling, 5453T) or αBCL-XL (1:100, Cell Signaling, 2764S) for at least 30 min. After a washing step with 100 μl PermWash Buffer, a goat anti-rabbit IgG (H+L) Alexa Fluor TM 647-conjugated antibody (1:1000, Invitrogen, A21245) was applied for 15 min. A final washing step with 100 μl PermWash Buffer was performed.

    Techniques: RNA Sequencing, Comparison, Flow Cytometry, Staining, In Vitro, Fluorescence